心不全治療市場：治療、タイプ、ステージ、エンドユーザー別-世界予測、2024～2030年

心不全治療市場規模は2023年に239億8,000万米ドルと推定され、2024年には261億6,000万米ドルに達し、CAGR 10.46%で2030年には481億3,000万米ドルに達すると予測されます。

心不全治療市場は、心臓疾患に罹患しやすくなっている高齢化社会が拍車をかけ、上昇軌道をたどっています。医療技術の進歩により心不全の治療と管理が強化される一方、新興経済諸国では所得水準の上昇と健康意識の高まりが医療費の増加に繋がっています。高度な治療に対する需要は、質の高い医療を熱望する人口に後押しされて上昇を続けており、政府や民間団体は研究開発（R&D）への投資を活発化させています。製薬業界やバイオテクノロジー業界は、最先端の医薬品や生物学的ソリューションを発表する態勢を整えており、患者モニタリングや分析などのデジタルヘルスツールは、医療水準を再定義する態勢を整えています。バイオテクノロジー新興企業のイノベーションと既存製薬企業のリーチを組み合わせた戦略的提携がこのセクター全体で形成されつつあり、個別化医療への動きは高度に個別化された治療法への扉を開いています。しかし、この市場は規制の複雑さと償還の課題に直面しています。研究開発と治療ソリューションに関連する莫大なコストは、市場成長の妨げとなる可能性があります。さらに、地域によっては心不全の過小診断や心不全への認識が低いこと、ジェネリック医薬品の競合につながる主要医薬品の特許切れ、患者の治療や生活習慣へのアドヒアランスの継続的な問題なども障害となります。事業拡大のためには、遺伝子治療や幹細胞治療の研究など、画期的な医薬品開発に注力する必要があります。診断や継続的ケアに人工知能や機械学習を取り入れ、遠隔患者監視システムを改善すれば、病院の再入院を大幅に減らし、外来治療を強化できると考えられます。また、併用療法の調査によって患者への恩恵が高まると同時に、費用対効果の高い治療法が生み出され、低所得者層への市場拡大が期待されます。

治療：心臓の健康管理のための処方薬や個別化薬への消費者の幅広いシフト

心不全の管理では、医療介入は機器ベースの治療から外科的選択肢まで多岐にわたります。バイレベル陽圧（BiPAP）装置は、交互の圧力レベルを提供することで呼吸努力を緩和し、それによって心臓の仕事量を減らします。外科的に植え込む両心室ペースメーカーは、心室収縮を同期させ、心拍出量を増加させる。持続陽圧呼吸器（CPAP）装置は、常に気道開放を維持することで、酸素飽和度を改善し、心臓への負担を軽減します。補助人工心臓（VAD）や植込み型左室補助人工心臓（LVAD）は、機能が低下した心臓を機械的にサポートし、十分な循環を確保します。植込み型除細動器（ICD）は、不整脈に対するショック療法です。薬剤的アプローチとしては、アンジオテンシンII受容体拮抗薬（ARB）やさまざまな血圧降下薬があり、それぞれ血管系を弛緩させ、血圧レベルを維持します。抗凝固薬や抗血小板薬は血栓リスクを軽減し、利尿薬は体液貯留を緩和します。硝酸薬は心臓の負担を減らすために血管拡大のために処方され、スタチンはさらなる心臓合併症を防ぐために脂質低下作用のために使用されます。外科的には、心臓再同期療法（CRT）が特殊なペースメーカーによって心室機能を最適化し、冠動脈バイパス術（CABG）や冠動脈血行再建術が心筋灌流を促進します。進行期では心臓弁置換術が弁機能障害に対処し、心臓移植は他の治療が奏功しない場合の決定的な解決策です。

タイプ：診断ツールと予後の革新は心臓の健康状態をよりよく管理するのに役立つ

心不全の診断ツールは、病態をタイムリーかつ正確に特定し、迅速かつ適切な治療介入を可能にするために極めて重要です。世界の罹患率と死亡率の主要原因としての心不全の蔓延により、高度で正確な診断ツールに対するニーズは常に高いです。心不全の診断に用いられる技術には、心エコー、MRI、CT、血液試験、ナトリウム利尿ペプチドスクリーニングなどがあります。心不全の予後評価は、起こりうる疾患の経過を決定し、治療の決定に影響を与え、期待される転帰について患者にカウンセリングを行うために不可欠です。予後予測モデルには、臨床評価、バイオマーカー、遺伝子試験、画像診断などが含まれることが多いです。心不全診断・予後予測市場には、心不全患者の予後を改善することを目的とした評判の高いプロバイダーによるさまざまなツールやサービスが存在します。このセグメントにおける最近の技術革新、特にAIと機械学習を活用した技術革新は、より個別化された正確なケアアプローチへの傾向を示しています。

地域別洞察

米国では、心不全が高齢者の入院の主要原因となっており、イノベーションを非常に重視する市場で先進的な治療への需要が高まっています。消費者は、安全性と有効性の確固としたエビデンスがあるブランドに惹かれ、最近の特許では革新的な製剤と送達メカニズムが注目されています。研究は最先端の遺伝子治療や幹細胞治療にますます焦点が当てられており、デジタルヘルスや個別化医療への大規模な投資によってその傾向はさらに強まっています。ミリオン・ハーツ」のようなプログラムは、心血管事故の予防に不可欠です。カナダは、心不全とそのリスクに関する高い意識を示し、幅広い治療アクセスを促進する医療制度に支えられています。同市場は、在宅モニタリング技術を含む画期的な治療法に対してオープンであり、将来のソリューションのために再生医療への投資を活用しています。欧州全域の心不全治療は、この地域の医療提供や償還に関する様々な制度を反映した多様な医療の恩恵を受けています。人口の高齢化と心臓病の蔓延は、効果的な治療法の必要性を後押ししており、政策と資金提供を通じて心血管系の負担を軽減することを目的とした欧州心臓ネットワークのイニシアチブによって促進されています。アジア太平洋では、心不全治療に対する需要が大きく変化しています。中国の医療セクターは、人口動態の変化やライフスタイルの変革に対応しながら急速に進化しており、政府の医療改革や現地での研究や特許出願の増加によって後押しされています。再生医療を中心とする日本の先進的医療研究は、超高齢化社会に対応し、消費者は国内の医療イノベーションを選好しています。インドでは中間所得層が増加しており、医療サービスの向上と医療費の低価格化を目指す全国的な医療イニシアティブに支えられ、心不全治療市場の拡大に寄与しています。中東・アフリカでは、心不全治療の状況は大きく異なります。アラブ首長国連邦やサウジアラビアのような裕福な中東諸国では、医療投資の強化により最先端の治療が増加しています。しかし、アフリカ市場は、「アフリカ・ハート・ネットワーク」のような団体や、現地製造や官民協同組合を奨励する戦略による取り組みを通じて、アクセスや価格の問題に直面しています。

FPNVポジショニングマトリックス

FPNVポジショニングマトリックスは、心不全治療市場の評価において極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を記載しています。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます。フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、心不全治療市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、このセグメントの競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています。

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を記載しています。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発とイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を記載しています。

本レポートは、以下のような主要な質問に対応しています。

1.心不全治療市場の市場規模と予測は？

2.心不全治療市場の予測期間中に投資を検討すべき製品、用途は何か？

3.心不全治療市場の技術動向と規制枠組みは？

4.心不全治療市場における主要ベンダーの市場シェアは？

5.心不全治療市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 高齢者人口における心血管疾患の罹患率の上昇
    • ライフスタイルの変化により心不全や不整脈に対する感受性が高まっている
    • 心不全の早期診断と管理の可用性と好み
  • 抑制要因
    • 心不全治療に関連する高額な費用と償還の問題
  • 機会
    • 心不全治療におけるイノベーションと開発
    • 政府の継続的な取り組みと民間セクターによる投資の増加
  • 課題
    • 心不全状態の管理に関する懸念
• 市場セグメンテーション分析
  • 治療：心臓の健康管理のために処方薬や個別化医薬品に消費者がシフト
  • タイプ：診断ツールと予後の革新は心臓の健康状態をより良く管理するのに役立つ
• 市場動向分析
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制枠組みの分析
• 顧客のカスタマイズ

第6章 心不全治療市場：治療別

• イントロダクション
• 医療機器
• 服薬
• 手術

第7章 心不全治療市場：タイプ別

• イントロダクション
• 診断
• 予後

第8章 心不全治療市場：ステージ別

• イントロダクション
• ステージA
• ステージB
• ステージC
• ステージD

第9章 心不全治療市場：エンドユーザー別

• イントロダクション
• クリニック
• 病院
• 医療研究機関

第10章 南北アメリカの心不全治療市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋の心不全治療市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの心不全治療市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析

第14章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. HEART FAILURE THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. HEART FAILURE THERAPEUTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. HEART FAILURE THERAPEUTICS MARKET DYNAMICS
• FIGURE 7. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 16. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 18. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 23. HEART FAILURE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 24. HEART FAILURE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. HEART FAILURE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BI-LEVEL POSITIVE AIR PRESSURE DEVICE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BI-LEVEL POSITIVE AIR PRESSURE DEVICE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BIVENTRICULAR PACEMAKER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BIVENTRICULAR PACEMAKER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CONTINUOUS POSITIVE AIR PRESSURE DEVICE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CONTINUOUS POSITIVE AIR PRESSURE DEVICE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART PUMPS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART PUMPS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY IMPLANTABLE LEFT VENTRICULAR ASSIST DEVICE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY IMPLANTABLE LEFT VENTRICULAR ASSIST DEVICE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANT MEDICINES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANT MEDICINES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET MEDICINES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET MEDICINES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BLOOD PRESSURE MAINTAINING AGENTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BLOOD PRESSURE MAINTAINING AGENTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DIURETICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DIURETICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY NITRATES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY NITRATES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STATINS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STATINS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 45. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
• TABLE 46. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
• TABLE 47. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CARDIAC RESYNCHRONIZATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 48. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CARDIAC RESYNCHRONIZATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 49. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 50. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 51. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CORONARY REVASCULARIZATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 52. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CORONARY REVASCULARIZATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 53. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART TRANSPLANT, BY REGION, 2018-2023 (USD MILLION)
• TABLE 54. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART TRANSPLANT, BY REGION, 2024-2030 (USD MILLION)
• TABLE 55. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART VALVE REPLACEMENT, BY REGION, 2018-2023 (USD MILLION)
• TABLE 56. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART VALVE REPLACEMENT, BY REGION, 2024-2030 (USD MILLION)
• TABLE 57. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 58. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 59. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 60. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 61. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PROGNOSIS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 62. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PROGNOSIS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 63. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2023 (USD MILLION)
• TABLE 64. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2024-2030 (USD MILLION)
• TABLE 65. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE A, BY REGION, 2018-2023 (USD MILLION)
• TABLE 66. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE A, BY REGION, 2024-2030 (USD MILLION)
• TABLE 67. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE B, BY REGION, 2018-2023 (USD MILLION)
• TABLE 68. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE B, BY REGION, 2024-2030 (USD MILLION)
• TABLE 69. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE C, BY REGION, 2018-2023 (USD MILLION)
• TABLE 70. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE C, BY REGION, 2024-2030 (USD MILLION)
• TABLE 71. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE D, BY REGION, 2018-2023 (USD MILLION)
• TABLE 72. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE D, BY REGION, 2024-2030 (USD MILLION)
• TABLE 73. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 74. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 75. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CLINIC, BY REGION, 2018-2023 (USD MILLION)
• TABLE 76. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CLINIC, BY REGION, 2024-2030 (USD MILLION)
• TABLE 77. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2023 (USD MILLION)
• TABLE 78. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2024-2030 (USD MILLION)
• TABLE 79. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL RESEARCH ORGANIZATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 80. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL RESEARCH ORGANIZATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 81. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 82. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 83. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
• TABLE 84. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2024-2030 (USD MILLION)
• TABLE 85. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2023 (USD MILLION)
• TABLE 86. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2024-2030 (USD MILLION)
• TABLE 87. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
• TABLE 88. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
• TABLE 89. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 90. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 91. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2023 (USD MILLION)
• TABLE 92. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2024-2030 (USD MILLION)
• TABLE 93. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 94. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 95. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 96. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 97. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 98. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 99. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
• TABLE 100. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2024-2030 (USD MILLION)
• TABLE 101. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2023 (USD MILLION)
• TABLE 102. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2024-2030 (USD MILLION)
• TABLE 103. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
• TABLE 104. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
• TABLE 105. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 106. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 107. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2023 (USD MILLION)
• TABLE 108. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2024-2030 (USD MILLION)
• TABLE 109. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 110. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 111. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 112. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 113. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
• TABLE 114. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2024-2030 (USD MILLION)
• TABLE 115. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2023 (USD MILLION)
• TABLE 116. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2024-2030 (USD MILLION)
• TABLE 117. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
• TABLE 118. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
• TABLE 119. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 120. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 121. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2023 (USD MILLION)
• TABLE 122. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2024-2030 (USD MILLION)
• TABLE 123. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 124. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 125. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 126. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 127. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
• TABLE 128. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2024-2030 (USD MILLION)
• TABLE 129. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2023 (USD MILLION)
• TABLE 130. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2024-2030 (USD MILLION)
• TABLE 131. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
• TABLE 132. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
• TABLE 133. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 134. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 135. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2023 (USD MILLION)
• TABLE 136. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2024-2030 (USD MILLION)
• TABLE 137. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 138. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 139. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 140. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 141. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
• TABLE 142. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2024-2030 (USD MILLION)
• TABLE 143. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2023 (USD MILLION)
• TABLE 144. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2024-2030 (USD MILLION)
• TABLE 145. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
• TABLE 146. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
• TABLE 147. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 148. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 149. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2023 (USD MILLION)
• TABLE 150. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2024-2030 (USD MILLION)
• TABLE 151. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 152. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 153. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 154. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 155. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
• TABLE 156. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2024-2030 (USD MILLION)
• TABLE 157. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2023 (USD MILLION)
• TABLE 158. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2024-2030 (USD MILLION)
• TABLE 159. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
• TABLE 160. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
• TABLE 161. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 162. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 163. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2023 (USD MILLION)
• TABLE 164. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2024-2030 (USD MILLION)
• TABLE 165. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 166. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 167. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 168. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 169. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 170. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 171. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
• TABLE 172. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2024-2030 (USD MILLION)
• TABLE 173. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2023 (USD MILLION)
• TABLE 174. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2024-2030 (USD MILLION)
• TABLE 175. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
• TABLE 176. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
• TABLE 177. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 178. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 179. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2023 (USD MILLION)
• TABLE 180. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2024-2030 (USD MILLION)
• TABLE 181. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 182. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 183. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 184. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 185. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 186. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 187. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
• TABLE 188. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2024-2030 (USD MILLION)
• TABLE 189. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2023 (USD MILLION)
• TABLE 190. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2024-2030 (USD MILLION)
• TABLE 191. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
• TABLE 192. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
• TABLE 193. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 194. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 195. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2023 (USD MILLION)
• TABLE 196. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2024-2030 (USD MILLION)
• TABLE 197. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 198. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 199. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 200. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 201. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
• TABLE 202. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2024-2030 (USD MILLION)
• TABLE 203. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2023 (USD MILLION)
• TABLE 204. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2024-2030 (USD MILLION)
• TABLE 205. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
• TABLE 206. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
• TABLE 207. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 208. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 209. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2023 (USD MILLION)
• TABLE 210. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2024-2030 (USD MILLION)
• TABLE 211. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 212. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 213. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 214. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 215. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
• TABLE 216. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2024-2030 (USD MILLION)
• TABLE 217. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2023 (USD MILLION)
• TABLE 218. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2024-2030 (USD MILLION)
• TABLE 219. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
• TABLE 220. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
• TABLE 221. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 222. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 223. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2023 (USD MILLION)
• TABLE 224. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2024-2030 (USD MILLION)
• TABLE 225. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 226. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 227. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 228. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 229. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
• TABLE 230. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2024-2030 (USD MILLION)
• TABLE 231. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2023 (USD MILLION)
• TABLE 232. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2024-2030 (USD MILLION)
• TABLE 233. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
• TABLE 234. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
• TABLE 235. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 236. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 237. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2023 (USD MILLION)
• TABLE 238. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2024-2030 (USD MILLION)
• TABLE 239. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 240. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 241. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 242. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 243. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
• TABLE 244. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2024-2030 (USD MILLION)
• TABLE 245. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2023 (USD MILLION)
• TABLE 246. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2024-2030 (USD MILLION)
• TABLE 247. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
• TABLE 248. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
• TABLE 249. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 250. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 251. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2023 (USD MILLION)
• TABLE 252. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2024-2030 (USD MILLION)
• TABLE 253. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 254. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 255. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 256. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 257. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
• TABLE 258. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2024-2030 (USD MILLION)
• TABLE 259. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2023 (USD MILLION)
• TABLE 260. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2024-2030 (USD MILLION)
• TABLE 261. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
• TABLE 262. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
• TABLE 263. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 264. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 265. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2023 (USD MILLION)
• TABLE 266. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2024-2030 (USD MILLION)
• TABLE 267. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 268. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 269. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 270. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 271. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
• TABLE 272. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2024-2030 (USD MILLION)
• TABLE 273. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2023 (USD MILLION)
• TABLE 274. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2024-2030 (USD MILLION)
• TABLE 275. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
• TABLE 276. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
• TABLE 277. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 278. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 279. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2023 (USD MILLION)
• TABLE 280. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2024-2030 (USD MILLION)
• TABLE 281. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 282. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 283. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 284. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 285. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
• TABLE 286. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2024-2030 (USD MILLION)
• TABLE 287. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2023 (USD MILLION)
• TABLE 288. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2024-2030 (USD MILLION)
• TABLE 289. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
• TABLE 290. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
• TABLE 291. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 292. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 293. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2023 (USD MILLION)
• TABLE 294. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2024-2030 (USD MILLION)
• TABLE 295. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 296. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 297. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 298. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 299. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
• TABLE 300. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2024-2030 (USD MILLION)
• TABLE 301. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2023 (USD MILLION)
• TABLE 302. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2024-2030 (USD MILLION)
• TABLE 303. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
• TABLE 304. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
• TABLE 305. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 306. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 307. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2023 (USD MILLION)
• TABLE 308. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2024-2030 (USD MILLION)
• TABLE 309. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 310. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 311. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 312. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 313. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
• TABLE 314. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2024-2030 (USD MILLION)
• TABLE 315. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2023 (USD MILLION)
• TABLE 316. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2024-2030 (USD MILLION)
• TABLE 317. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
• TABLE 318. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
• TABLE 319. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 320. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 321. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2023 (USD MILLION)
• TABLE 322. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2024-2030 (USD MILLION)
• TABLE 323. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 324. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 325. THAILAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
• TABLE 326. THAILAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
• TABLE 327. THAILAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2023 (USD MILLION)
• TABLE 328. THAI

[191 Pages Report] The Heart Failure Therapeutics Market size was estimated at USD 23.98 billion in 2023 and expected to reach USD 26.16 billion in 2024, at a CAGR 10.46% to reach USD 48.13 billion by 2030.

The heart failure therapeutics market is observing an upward trajectory, spurred by an aging population that is increasingly susceptible to cardiac conditions. Advances in medical technology are enhancing treatment and management of heart failure, while rising income levels and health awareness in developing economies are leading to greater healthcare expenditure. The demand for sophisticated treatments continues to climb, driven by a population eager for high-quality care, prompting governments and private entities to boost investment in research and development (R&D). Amidst these growth factors lie considerable opportunities; the pharmaceutical and biotech industries are poised to unveil cutting-edge drugs and biological solutions, with digital health tools, such as patient monitoring and analytics, poised to redefine care standards. Strategic alliances are forming across the sector, combining the innovation of biotech start-ups with the reach of established pharmaceutical companies, and the movement towards personalized medicine opens doors to highly individualized therapies. However, this market faces regulatory complexities and reimbursement challenges. The steep costs associated with R&D and therapeutic solutions can hinder market growth. Further obstructions include the underdiagnosis and unawareness of heart failure in some regions, the expiration of key drug patents leading to generic competition, and the ongoing issue of patient adherence to treatment and lifestyle regimes. For business expansion, the industry must zero in on revolutionary drug development, including gene and stem cell therapy research. Incorporating artificial intelligence and machine learning into diagnostics and ongoing care, and improving remote patient monitoring systems could drastically cut hospital readmissions and bolster outpatient care. Research into combination therapies may yield enhanced benefits for patients, while also creating cost-effective treatments that will extend the market's reach into low-income regions.

Treatment: Extensive consumers shift toward prescribed and personalized medicines for heart health management

In managing heart failure, medical intervention ranges from device-based therapies to surgical options. Bi-level Positive Air Pressure (BiPAP) devices ease the respiratory effort by providing alternating levels of pressure, thereby reducing cardiac workload. Biventricular pacemakers, surgically implanted, synchronize ventricular contractions, enhancing cardiac output. Continuous Positive Airway Pressure (CPAP) devices consistently support open airways, which improves oxygen saturation and eases strain on the heart. Ventricular assist devices (VADs), or heart pumps, and Implantable Left Ventricular Assist Devices (LVADs) offer mechanical support to compromised hearts, ensuring adequate circulation. Implantable Cardioverter-Defibrillators (ICDs) safeguard against arrhythmic events with corrective shocks. Pharmaceutical approaches include Angiotensin II Receptor Blockers (ARBs) and various blood pressure medications that relax vasculature and maintain pressure levels, respectively. Anticoagulants and antiplatelet medications reduce thrombotic risks, whereas diuretics mitigate fluid retention. Nitrates are prescribed for vascular dilation to decrease cardiac load, and statins are utilized for their lipid-lowering effects, preventing further cardiac complications. Surgically, Cardiac Resynchronization Therapy (CRT) optimizes ventricular function through a specialized pacemaker, while Coronary Artery Bypass Grafting (CABG) and Coronary Revascularization procedures enhance myocardial perfusion. In advanced stages, heart valve replacement surgery addresses valvular dysfunction, and heart transplant remains the definitive solution when other interventions fail.

Type: Innovations in the diagnostic tools and prognosis helps in better managing the heart health condition

Diagnostic tools for heart failure are crucial for timely and accurate identification of the condition, thus enabling prompt and appropriate therapeutic interventions. The need for advanced and precise diagnostic tools is consistently high, driven by the prevalence of heart failure as a leading cause of morbidity and mortality worldwide. Technologies utilized in the diagnosis of heart failure include echocardiography, magnetic resonance imaging (MRI), computed tomography (CT), blood tests, and natriuretic peptide screening. Prognostic evaluation in heart failure is essential for determining the likely course of the disease, influencing treatment decisions, and counseling patients regarding expected outcomes. Prognostic models often include clinical assessment, biomarkers, genetic testing, and imaging modalities. The market for heart failure diagnostics and prognostics boasts a variety of tools and services from numerous reputable providers, all aimed at improving outcomes for heart failure patients. Recent innovations within this space, particularly those leveraging AI and machine learning, signal a trend towards more personalized and precise care approaches.

Regional Insights

In the United States, heart failure is a primary cause of hospitalization among seniors, fueling the demand for advanced therapeutics in a market that highly values innovation. Consumers gravitate towards brands with firm evidence of safety and effectiveness, with recent patents spotlighting innovative formulations and delivery mechanisms. Research is increasingly focused on cutting-edge gene and stem cell therapies, amplified by significant investments in digital health and personalized medicine. Programs such as 'Million Hearts' are crucial in preventing cardiovascular incidents. Canada demonstrates high awareness around heart failure and its risks, supported by a healthcare system that promotes wide treatment access. The market is open to groundbreaking treatments, including home-based monitoring technologies, and leverages investments in regenerative medicine for future solutions. Heart failure therapeutics across Europe benefit from a diverse healthcare landscape, reflecting the region's various systems of healthcare delivery and reimbursement. The aging population and prevalence of heart diseases drive the need for effective treatments, facilitated by initiatives from the European Heart Network aimed at reducing cardiovascular burdens through policies and funding. The Asia-Pacific region is undergoing significant shifts in heart failure treatment demands. China's healthcare sector is evolving rapidly, responding to demographic shifts and lifestyle transformations, bolstered by government healthcare reforms and an uptick in local research and patent filings. Japan's advanced healthcare research, particularly in regenerative medicine, caters to its super-aged society, with consumers showing a preference for local medical innovations. India's growing middle class contributes to an expanding heart failure therapeutics market, further supported by nationwide health initiatives seeking to enhance healthcare services and affordability. In the Middle East and Africa, the heart failure therapeutics landscape varies widely. Affluent Middle Eastern countries like the UAE and Saudi Arabia are seeing an uptick in state-of-the-art treatments powered by enhanced healthcare investments. However, African markets confront access and affordability issues, tackled through efforts by entities like the 'Africa Heart Network' and strategies that encourage local manufacturing and public-private cooperatives.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Heart Failure Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Heart Failure Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Heart Failure Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, ABIOMED, Inc., Alembic Pharmaceuticals Limited, Amgen Inc., AstraZeneca PLC, Bayer AG, Beckman Coulter, Inc., Berlin Heart GmbH, Biosensors International Group, Ltd., Biotronik SE & Co. KG, Boston Scientific Corporation, Bristol-Myers Squibb Company, Cardiol Therapeutics Inc., Cipla Limited, Dr. Reddy's Laboratories Limited, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Impulse Dynamics, Jarvik Heart, Inc., Johnson & Johnson, LivaNova, PLC, Medtronic PLC, Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Orion Corporation, Osypka Medical GmbH, Pfizer, Inc., and Verve Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Heart Failure Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Treatment
  • Medical Devices
    • Bi-level positive air pressure device
    • Biventricular Pacemaker
    • Continuous Positive Air Pressure Device
    • Heart Pumps
    • Implantable Cardioverter-Defibrillators
    • Implantable Left Ventricular Assist Device

• Medicines
  • Angiotensin II Receptor Blockers
  • Anticoagulant Medicines
  • Antiplatelet Medicines
  • Blood Pressure Maintaining Agents
  • Diuretics
  • Nitrates
  • Statins

• Surgery
  • Cardiac Resynchronization
  • Coronary Artery Bypass Grafting
  • Coronary Revascularization
  • Heart Transplant
  • Heart Valve Replacement
• Type
  • Diagnosis
  • Prognosis

• Stage
  • Stage A
  • Stage B
  • Stage C
  • Stage D

• End User
  • Clinic
  • Hospital
  • Medical Research Organization

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Heart Failure Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Heart Failure Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Heart Failure Therapeutics Market?

4. What is the market share of the leading vendors in the Heart Failure Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Heart Failure Therapeutics Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising Prevalence of Cardiovascular Diseases Among Geriatric Population
    • 5.1.1.2. Growing Susceptibility to Heart Failure and Arrhythmia Owing to Changing Lifestyles
    • 5.1.1.3. Availability and Preferences of Early Diagnosis and Management for Heart Failure
  • 5.1.2. Restraints
    • 5.1.2.1. High Cost and Reimbursement Issues Related to Heart Failure Treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Innovations and Development in the Heart Failure Therapeutics
    • 5.1.3.2. Ongoing Government Initiatives and Increasing Investments by Private Sectors
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns Related to Management of Heart Failure Condition
• 5.2. Market Segmentation Analysis
  • 5.2.1. Treatment: Extensive consumers shift toward prescribed and personalized medicines for heart health management
  • 5.2.2. Type: Innovations in the diagnostic tools and prognosis helps in better managing the heart health condition
• 5.3. Market Trend Analysis
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework Analysis
• 5.9. Client Customization

6. Heart Failure Therapeutics Market, by Treatment

• 6.1. Introduction
• 6.2. Medical Devices
• 6.3. Medicines
• 6.4. Surgery

7. Heart Failure Therapeutics Market, by Type

• 7.1. Introduction
• 7.2. Diagnosis
• 7.3. Prognosis

8. Heart Failure Therapeutics Market, by Stage

• 8.1. Introduction
• 8.2. Stage A
• 8.3. Stage B
• 8.4. Stage C
• 8.5. Stage D

9. Heart Failure Therapeutics Market, by End User

• 9.1. Introduction
• 9.2. Clinic
• 9.3. Hospital
• 9.4. Medical Research Organization

10. Americas Heart Failure Therapeutics Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Heart Failure Therapeutics Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Heart Failure Therapeutics Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. US FDA approves Medtronic's system for heart condition
  • 13.3.2. J&J drops USD 400 million to acquire new type of stroke-reducing heart implant
  • 13.3.3. FDA Clears MRI Use with Cardiac Contractility Modulation Device

14. Competitive Portfolio

• 14.1. Key Company Profiles
• 14.2. Key Product Portfolio